Improved Therapy by Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody

We examined whether a pretargeting method using a new, recombinant anti-CD20 bispecific antibody (bsMAb) followed by (90)Y-DOTA-peptide could reduce hematological toxicity yet improve therapeutic responses, compared to conventional (90)Y-anti-CD20 IgG and a chemically-conjugated bsMAb. TF4, a humani...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Sharkey, Robert M., Karacay, Habibe, Litwin, Samuel, Rossi, Edmund A., McBride, William J., Chang, Chein-Hsing, Goldenberg, David M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2585743/
https://ncbi.nlm.nih.gov/pubmed/18593929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-0037
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky